Merck's Gardasil vaccine saw a 55% increase over last year’s third quarter, netting $1.05 billion in global sales for the third quarter of 2018. Thanks to worldwide sales, the Gardasil vaccine has become the top money maker for Merck. FiercePharma, the marketing trade publication for vaccine manufacturers, reports that Merck’s Gardasil has been propelling the pharma giant’s vaccine unit in recent quarters, and that doesn't look like it'll be changing. The company sees more growth ahead thanks to an “unprecedented increase in worldwide demand” for HPV vaccines, an executive said. Addressing the vaccine's performance on a recent conference call, Merck’s president of global human health Adam Schechter said the company is “seeing unprecedented increase in worldwide demand for the HPV vaccines.” He said global demand has “doubled in the last year alone.” Meanwhile, the carnage left behind from mass Gardasil vaccination programs continues to get world-wide exposure, as doctors, scientists, and victims look for ways to oppose mass Gardasil vaccination programs. A recent gathering in Ireland at an IFICA conference brought together many world leaders to discuss the Gardasil problem, and another meeting is scheduled in the U.S. in 2019 during the Autism One conference, at the 4th Annual International HPV Vaccine Education Symposium.
The lawfirm of Maglio Christopher & Toale, P.A. announced earlier this month (July, 2018) that they had negotiated a $101 million dollar settlement for an infant who suffered a severe reaction to the Measles Mumps Rubella (MMR) vaccine. A one-year-old healthy baby girl, who was already walking and climbing, received vaccinations for Measles Mumps Rubella (MMR), Hepatitis A, Haemophilus Influenzae type B (Hib), Prevnar (pneumonia), and Varicella (chickenpox) on February 13, 2013. That evening, the mother noticed the baby was irritable and feverish. After a call to the pediatrician, the doctor advised Mom to give her Tylenol and Benadryl. The fever continued for several days, and on the evening before the baby’s scheduled pediatrician visit, the baby began having severe seizures. She was rushed to the emergency room. She went into cardiac and respiratory arrest, and doctors placed her on a ventilator. The seizures and cardiac arrest left the baby with a severe brain injury, encephalopathy, cortical vision impairment, truncal hypotonia (low muscle tone), and kidney failure. After months of treatment at the hospital, the baby finally went home, but her disabilities required specialized medical care and supervision around the clock for the rest of her life. The $101 million dollar settlement will pay for the child’s constant high-level medical care for the rest of her life. The family received a lump sum of $1 million dollars to cover the immediate costs of medical bills and expenses. The rest will be paid out through an annuity over the child’s lifetime. Don't expect to read this story in the Big Pharma-sponsored corporate "mainstream" media, where the official doctrine is that vaccines are "safe and effective."
Merck Receives FDA Priority Review to Expand Dangerous Gardasil Vaccine to Women and Men Ages 27 to 45
Gardasil vaccine manufacturer, Merck, announced earlier this month (June, 2018) that the U.S. Food and Drug Administration (FDA) has granted them a "Priority Review" to approve the dangerous and controversial Gardasil 9 vaccine to women and men, ages 27 to 45. The Gardasil vaccine is currently approved for girls and boys, ages 9 through 26. The request by Merck to expand its market to women and men, ages 27 to 45, and the FDA's approval to grant it a Priority Review by October 6, 2018, follows 10 years after the FDA struck down a similar request to expand the older version of Gardasil to the same age group. Besides the hundreds of stories of young women being injured or even killed by the Gardasil vaccine, as well as the lawsuits mounting in countries outside the U.S., the published data regarding Gardasil just keeps getting worse. Will the FDA consider these studies in determining if Gardasil should be expanded to a larger population? Shouldn't the FDA instead be determining if Gardasil should even stay in the market, as other countries are beginning to ask?
Last month (May, 2018) we published a report from the vaccine marketing trade publication, Fierce Pharma, that Merck's sales this year were beating financial forecasts, primarily due to its entrance into the China market for its top-selling Gardasil HPV vaccine. Fierce Pharma reported at that time that the Gardasil vaccine was fast-tracked for approval into the China market: "Late last month, the Chinese FDA granted Gardasil 9 a conditional approval only nine days into a review." Now, Fierce Pharma is reporting that Gardasil's acceptance into the China market has produced instant billionaires.
Merck’s Fosamax Fraud Demonstrates How Big Pharma and CDC Spin Statistics to Sell Ineffective Vaccines and Drugs
It has been over a decade since I came to the realization that the entire profession of medicine had been bamboozled by the propaganda coming from the Big Pharma drug and vaccine maker, Merck & Company, that its so-called “fracture-preventative” drug Fosamax had defrauded us doctors and our patients by falsely claiming a “50% efficacy rate” in the prevention of bone fractures in osteopenic/osteoporotic women. By doing a little math, I understood that the honest truth of the matter was that patients who took the drug for four years had a miniscule 1-2% absolute risk reduction (AAR) in the incidence of fractures, which is a much more realistic figure that Merck, being a sociopathic entity that is inclined to tell half-truths or outright lies, chose not to use in its advertisements. It is a fact that being truthful in the drug or vaccine industry is an impediment to selling product, because they would be admitting they were selling a lousy, fraudulent, relatively ineffective or dangerous drug or vaccine. In other words, Big Pharma/BigVaccine is still successfully bamboozling us doctors and patients (as well as Big Media, the CDC, the FDA, the AMA, the AAP, the APA, the AAFP, the NIH, the NIMH, Wall Street and our politicians) with the old deceptive tactic of using relative risk reduction statistics about vaccine efficacy rather than honestly telling us the more truthful absolute risk reduction figures whenever they are rolling out their newest – and increasingly unaffordable – vaccines. Therefore, I devote the remainder of this column to reporting some excerpts from the internet and end with some examples of published studies from courageous researchers who have gone up against the drug industry and reported the important statistics that we should all demand to know when a vaccine (or drug) is being sold to us.
The pharmaceutical marketing trade publication, Fierce Pharma, announced this month (May 2018) that Merck has beat Wall Street expectations for their Gardasil vaccine sales during the first quarter of 2018, achieving 24% growth with $660 million for the HPV vaccine. The report notes that sales in the U.S. are declining, attributing the decline in sales to the CDC decision to reduce their recommendation of the Gardasil vaccine to be only two doses, instead of three. Nothing is mentioned about declining public opinion regarding Gardasil, nor the numerous lawsuits against the company outside the U.S. The increase in sales for Gardasil is attributed to their entrance into the China market. The original vaccine won Chinese approval last year, while late last month the Chinese FDA granted Gardasil 9 a conditional approval only nine days into a review.
Pharmaceutical giant, Merck, is facing charges of fraud in lawsuits filed in U.S. courts regarding their vaccine products. This is important information for the public to know, given the fact that the ever-growing vaccine market is expected to exceed $70 billion within the next few years, and that many states are trying to pass legislation to mandate vaccines without informed consent, all in the name of "the greater good" for public health. Federal government agencies tasked with protecting public health, along with the corporate "mainstream" media, which reportedly receives up to 70% of its advertising revenue from pharmaceutical companies, continue to censor any negative information regarding vaccines that could affect sales. And since one cannot sue a pharmaceutical company for damages or deaths due to vaccines in the United States, where they enjoy legal immunity, it is rare that a pharmaceutical company faces a day in court related to corruption or fraud for bad vaccine products. Therefore, one needs to turn to either the alternative media such as Health Impact News, or the foreign media outside the U.S., to learn about the dangers of vaccines, and the corruption behind many of them. There are currently two major federal lawsuits against Merck that are being litigated in U.S. courts: a whistleblower lawsuit from former Merck scientists claiming fraud regarding the MMR vaccine, which has been in the courts for eight years now, and a lawsuit against the Gardasil vaccine claiming fraud from a 16-year-old girl who allegedly suffered Postural Orthostatic Tachycardia Syndrome (POTS) after receiving the Gardasil vaccine.
People who have adverse reactions to vaccinations are marginalized, minimized and denied just compensation for their injuries. We take a look at the personal story of a man just injured from a vaccination, who had ironically worked for the California Senator who authored SB277 that removes parental informed consent for vaccinations. And a former drug rep for Merck who sold vaccines tells why he would never vaccinate his children.
In a brief mention in the mainstream media that as far as we can tell only Reuters reported, former Merck vaccine scientists, who have become whistleblowers and have had a federal lawsuit pending against Merck since 2010 for vaccine fraud, have filed another court document in their case accusing Merck of withholding evidence and not complying with court orders.
Julie Gerberding was in charge of the Centers for Disease Control and Prevention (CDC) from 2002 to 2009, which includes the years the FDA approved the Merck Gardasil vaccine. Soon after she took over the CDC, she reportedly completely overhauled the agency’s organizational structure, and many of the CDC’s senior scientists and leaders either left or announced plans to leave. Some have claimed that almost all of the replacements Julie Gerberding appointed had ties to the vaccine industry. Gerberding resigned from the CDC on January 20, 2009, and took over as the president of Merck’s Vaccine division, a 5 billion dollar a year operation, and the supplier of the largest number of vaccines the CDC recommends. It was reported earlier this month that Dr. Gerberding, now the executive vice president of pharmaceutical giant Merck, sold 38,368 of her shares in Merck stock for $2,340,064.32. She still holds 31,985 shares of the company’s stock, valued at about $2 million.